Condition: Asthma
Intervention: Drug: salbutamol sulfate + ipratropium bromide
Sponsor: Boehringer Ingelheim
Terminated – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
CLINICAL PHARMACOLOGY STUDY OF A FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 50µg PLUS FORMOTEROL FUMARATE 6 µg VERSUS THE FREE COMBINATION OF BECLOMETHASONE HFA pMDI AND FORMOTEROL HFA pMDI AVAILABLE ON THE MARKET USING THE AEROCHAMBER PLUS™ SPACER DEVICE IN ASTHMATIC CHILDREN
Condition: Asthma
Interventions: Drug: CHF1535 pMDI + AC Plus; Drug: BDP and Formoterol + AC Plus
Sponsors: Chiesi Farmaceutici S.p.A.; Chiesi Farmaceutici S.p.A.
Completed – verified April 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Inhaler spacer devices to treat asthma in children – Nursing Times
|
Inhaler spacer devices to treat asthma in children
Nursing Times Drawing on literature searches and professional experience, this article discusses the treatment of asthma with pressurised metered dose inhalers (pMDIs). It demonstrates the need for pMDIs, and presents the health and cost benefits of using a pMDI … |
View full post on asthma – Google News
Managing asthma: the importance of spacer – Riverhead LOCAL
|
Managing asthma: the importance of spacer
Riverhead LOCAL Asthma is one of the most common chronic conditions in the nation with an incidence rate of one in 9 children and one in 12 adults in NY state. The highest rate of asthma occurs in NYC, Nassau and Suffolk counties. Studies have demonstrated that more … |
View full post on asthma – Google News
School nurse invents new asthma spacer – Nursing Times
|
School nurse invents new asthma spacer
Nursing Times A Norfolk school nurse has won a prestigious award for inventing a “pocket sized” asthma spacer. Paul Watson, a school nurse from Norfolk Community Health and Care NHS Trust, received the 2011 Alumni Success in BusinessAward from Anglia Ruskin … |
View full post on asthma – Google News
Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers
Condition: Asthma
Interventions: Drug: Seretide 250(8puffs) via Evohaler actuator; Drug: Seretide 250 (8 puffs)/placebo via Volumatic spacer; Drug: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer; Drug: Seretide 250/placebo via Synchro-Breathe
Sponsor: University of Dundee
Completed – verified December 2009
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days